- Trial phase
- Phase 3
- Time to market
- At least 3-5 years; Phase 3 BEYOND trial estimated to complete Jan 2028, followed by regulatory filing and review.
- Why 3/10
- No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months; the Phase 3 BEYOND trial's estimated primary completion is Aug 2027. Zigakibart is one of over 100 pipeline programs at a $200B+ diversified pharma, so even a positive readout would have limited impact on NVS shares.
The next meaningful catalyst is the Phase 3 BEYOND primary completion (estimated Aug 2027) or any potential interim analysis. For a large-cap like Novartis, zigakibart alone is unlikely to drive material share-price moves. Watch for topline BEYOND results and any accelerated approval filing strategy, but this is a multi-year story within a diversified pharma portfolio.
Price Chart
Executive Summary
Zigakibart is an investigational anti-APRIL monoclonal antibody in Phase 3 development by Novartis (NYSE: NVS) for IgA nephropathy (IgAN), a progressive kidney disease. It was originally developed by Chinook Therapeutics, which Novartis acquired in 2023. Phase 1/2 data showed ~60% proteinuria reduction and eGFR stabilization over 100+ weeks with a favorable safety profile. The pivotal Phase 3 BEYOND trial (NCT05852938) is active but not recruiting, with estimated primary completion in August 2027. Recent 124-week data presented at ASN Kidney Week 2026 (Oct 23) showed sustained efficacy. No BLA has been filed and no PDUFA date exists. For Novartis, a $200B+ diversified pharma with a pipeline of over 100 programs, zigakibart is a small component, and the stock is unlikely to move materially on this drug alone in the near term.
How It Works
Zigakibart is a lab-engineered antibody that blocks a signaling protein called APRIL, which is overactive in IgA nephropathy (IgAN). By neutralizing APRIL, the drug reduces the production of abnormal IgA antibodies that build up in the kidneys and cause inflammation and damage. It is given as a subcutaneous (under-the-skin) injection every two weeks.
Trial Status
The pivotal Phase 3 BEYOND study (NCT05852938, ~383 patients) is active but not recruiting, with estimated primary completion Aug 2027 and final completion Jan 2028. A Phase 3 open-label extension (NCT06858319) is recruiting. A Phase 3b combination trial with atrasentan (LUMINA IgAN, NCT07850752) is planned to start Dec 2026. Phase 1/2 data through 124 weeks were presented at ASN Kidney Week 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 BEYOND primary completion (estimated Aug 2027), topline proteinuria and eGFR data
- LUMINA IgAN Phase 3b trial initiation (estimated Dec 2026), zigakibart + atrasentan combination study
- Potential interim analysis of BEYOND trial (if pre-specified)
- Any decision on accelerated approval filing strategy based on proteinuria data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report